NewsBenzingaHarvard Bioscience relève ses prévisions de ventes pour l’exercice 2026 de 88,281 M$-90,012 M$ à 89,147 M$-90,877 M$, contre 89,794 M$ estimés Harvard Bioscience relève ses prévisions de ventes pour l’exercice 2026 de 88,281 M$-90,012 M$ à 89,147 M$-90,877 M$, contre 89,794 M$ estimés Benzinga 2026.11.10 12:04 (GMT+0) Open on Benzinga Other news NRX Pharmaceuticals Q3 EPS $(0.05) Beats $(0.21) Estimate, Sales $1.159M Miss $1.300M Estimate HUYA Q3 Adj. EPS $0.03 Up From $0.02 YoY, Sales $261.441M Up From $237.147M YoY Adam Schiff Slams Corporate Executives Over Unreturned Trump Tariff Money: ‘Companies Got Tariff Refunds, Consumers Got…’ Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL Ford Recalls 60,956 Transit Vehicles Over Body Control Module Software Error That Can Shut Off Trailer Lights, Raising Crash Risk Top Wall Street Forecasters Revamp Energizer Expectations Ahead Of Q4 Earnings
Adam Schiff Slams Corporate Executives Over Unreturned Trump Tariff Money: ‘Companies Got Tariff Refunds, Consumers Got…’
Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL
Ford Recalls 60,956 Transit Vehicles Over Body Control Module Software Error That Can Shut Off Trailer Lights, Raising Crash Risk